SCHEDULE 13G

CUSIP No.

Names of Reporting Persons

ADAR1 Capital Management, LLC

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

TEXAS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,434,941.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,434,941.00

Aggregate Amount Beneficially Owned by Each Reporting Person

2,434,941.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

6.0 %

Type of Reporting Person (See Instructions)

IA, OO

Comment for Type of Reporting Person: Includes (i) 2,038,429 shares of Class A common stock, par value $0.0001 per share ("Common Stock") held by ADAR1 Partners, LP, (ii) 295,020 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC and (iii) 101,492 shares of Common Stock held by other separately managed accounts as of March 31, 2026. As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC and the separately managed accounts referenced above, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC and the separately managed accounts. Based on 40,395,480 shares of Common Stock of OnKure Therapeutics, Inc. (the "Issuer") outstanding as of March 31, 2026, reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on May 5, 2026.

SCHEDULE 13G

CUSIP No.

Names of Reporting Persons

ADAR1 Capital Management GP, LLC

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

TEXAS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,038,429.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,038,429.00

Aggregate Amount Beneficially Owned by Each Reporting Person

2,038,429.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

5.0 %

Type of Reporting Person (See Instructions)

Comment for Type of Reporting Person: Includes 2,038,429 shares of Class A common stock, par value $0.0001 per share ("Common Stock") held by ADAR1 Partners, LP as of March 31, 2026. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. Based on 40,395,480 shares of Common Stock of OnKure Therapeutics, Inc. (the "Issuer") outstanding as of March 31, 2026, reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on May 5, 2026.

SCHEDULE 13G

CUSIP No.

Names of Reporting Persons

Daniel Schneeberger

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

TEXAS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,434,941.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,434,941.00

Aggregate Amount Beneficially Owned by Each Reporting Person

2,434,941.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

6.0 %

Type of Reporting Person (See Instructions)

HC, IN

Comment for Type of Reporting Person: Includes (i) 2,038,429 shares of Class A common stock, par value $0.0001 per share ("Common Stock") held by ADAR1 Partners, LP, (ii) 295,020 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC and (iii) 101,492 shares of Common Stock held by other separately managed accounts as of March 31, 2026. As the manager of ADAR1 Capital Management, LLC, and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC and the separately managed accounts referenced above. Based on 40,395,480 shares of Common Stock of OnKure Therapeutics, Inc. (the "Issuer") outstanding as of March 31, 2026, reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on May 5, 2026.

SCHEDULE 13G

Item 1.

(a)

Name of issuer:

OnKure Therapeutics, Inc.

(b)

Address of issuer's principal executive offices:

6707 Winchester Circle, Suite 400 Boulder, CO 80301

Item 2.

(a)

Name of person filing:

This Schedule is being filed on behalf of each of the following persons (each, a "Reporting Person" and collectively, the "Reporting Persons"): (i) ADAR1 Capital Management, LLC ("ADAR1 Capital Management"); (ii) ADAR1 Capital Management GP, LLC ("ADAR1 General Partner"); and (iii) Daniel Schneeberger ("Mr. Schneeberger").

(b)

Address or principal business office or, if none, residence:

The address of the principal business office of each of the Reporting Persons is 3503 Wild Cherry Drive, Building 9, Austin, Texas 78738.

(c)

Citizenship:

(i) ADAR1 Capital Management is a Texas limited liability company; (ii) ADAR1 General Partner is a Texas limited liability company; and (iii) Mr. Schneeberger is a citizen of Switzerland.

(d)

Title of class of securities:

Class A Common Stock, par value $0.0001 per share

(e)

CUSIP No.:

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k)

Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4.

Ownership

(a)

Amount beneficially owned: